{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:54:33Z","timestamp":1776372873941,"version":"3.51.2"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clbc.2019.06.008","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T02:08:01Z","timestamp":1562810881000},"page":"e89-e98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients"],"prefix":"10.1016","volume":"20","author":[{"given":"Luca","family":"Cantini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirco","family":"Pistelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Merloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Bastianelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Della Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Santinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Savini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Maccaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucrezia","family":"Diodati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2019.06.008_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER2lneu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.clbc.2019.06.008_bib2","first-page":"923","article-title":"Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study","volume":"9","author":"Joensuu","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2019.06.008_bib3","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.06.008_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2 positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2019.06.008_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/95.2.142","article-title":"Quantitative association between HER2\/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer","volume":"95","author":"Konecny","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2019.06.008_bib6","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"4","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clbc.2019.06.008_bib7","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.clbc.2019.06.008_bib8","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/j.breast.2013.07.029","article-title":"Trastuzumab for patients with HER2-positive breast cancer: delivery, duration and combination therapies","volume":"22","author":"Pinto","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2019.06.008_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2016.11.002","article-title":"Escalating and de-escalating treatment in HER2-positive early breast cancer","volume":"52","author":"Joensuu","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clbc.2019.06.008_bib10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2019.06.008_bib11","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/bcr3324","article-title":"Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study","volume":"14","author":"Vaz-Luis","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2019.06.008_bib12","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.06.008_bib13","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2019.06.008_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1056\/NEJMe1706150","article-title":"Questioning our APHINITY for more","volume":"377","author":"Miller","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2019.06.008_bib15","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","article-title":"Annual hazard rates of recurrence for breast cancer after primary therapy","volume":"14","author":"Saphner","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.06.008_bib16","first-page":"1","article-title":"Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee","volume":"854","year":"1995","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1016\/j.clbc.2019.06.008_bib17","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1016\/j.ejca.2013.07.016","article-title":"Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients","volume":"49","author":"Mazzarella","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2019.06.008_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.breast.2017.11.004","article-title":"Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer","volume":"37","author":"Martel","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2019.06.008_bib19","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2019.06.008_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-016-3923-8","article-title":"Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy","volume":"159","author":"Gennari","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2019.06.008_bib21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000350002","article-title":"Impact of body mass index on prognostically relevant breast cancer tumor characteristics","volume":"8","author":"Eichholzer","year":"2013","journal-title":"Breast Care"},{"key":"10.1016\/j.clbc.2019.06.008_bib22","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1128\/MCB.23.23.8691-8703.2003","article-title":"Increased malignancy of neu-induced mammary tumors overexpressing active transforming growth factor 1","volume":"23","author":"Muraoka","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clbc.2019.06.008_bib23","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00432-011-1057-2","article-title":"Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis","volume":"137","author":"Chen","year":"2011","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clbc.2019.06.008_bib24","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1158\/0008-5472.CAN-11-0308","article-title":"HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis","volume":"71","author":"Hartman","year":"2011","journal-title":"Cancer Res"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820919300813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820919300813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:18:57Z","timestamp":1761513537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820919300813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1526820919300813"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2019.06.008","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2019.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}